文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SARS-CoV-2 疫苗全面综述:辉瑞、莫德纳和强生。

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.

机构信息

Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Clearwater, FL, USA.

Department of Health Sciences, Marieb College of Health & Human Services, Florida Gulf Coast University, Fort Myers, FL, USA.

出版信息

Hum Vaccin Immunother. 2022 Dec 31;18(1):2002083. doi: 10.1080/21645515.2021.2002083. Epub 2022 Feb 7.


DOI:10.1080/21645515.2021.2002083
PMID:35130825
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8862159/
Abstract

The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed by Pfizer, Moderna, and Johnson & Johnson. Pfizer and Moderna developed mRNA vaccines, encoding the spike protein of SARS-CoV-2, whereas Johnson & Johnson developed an adenovirus vector-based vaccine. Safety has been shown in a large cohort of participants in clinical trials as well as the general population since emergency approval of vaccine administration in the US. Clinical trial results showed the Pfizer and Moderna vaccines to be 95.0%, and the Johnson & Johnson vaccine to be 66.0% effective in protecting against moderate and symptomatic SARS-CoV-2 infection. It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.

摘要

2020 年 3 月,新型冠状病毒疫情被宣布为大流行。我们正在通过讨论辉瑞、莫德纳和强生公司开发的疫苗的作用机制、管理、副作用和疗效,来审查美国批准使用的 COVID-19 疫苗。辉瑞和莫德纳公司开发了编码 SARS-CoV-2 刺突蛋白的 mRNA 疫苗,而强生公司开发了一种基于腺病毒载体的疫苗。自美国紧急批准疫苗接种以来,大量临床试验参与者和普通人群的安全性已得到证实。临床试验结果显示,辉瑞和莫德纳疫苗对预防中度和有症状的 SARS-CoV-2 感染的有效率分别为 95.0%和 66.0%,强生疫苗为 66.0%。随着这些疫苗在不同年龄组中的测试以及 SARS-CoV-2 冠状病毒新型变体的出现,及时更新医学文献以跟踪这些疫苗的临床试验非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/34426ea6ab2f/KHVI_A_2002083_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/5e91b2b6dcbf/KHVI_A_2002083_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/827ec685c8dd/KHVI_A_2002083_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/34426ea6ab2f/KHVI_A_2002083_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/5e91b2b6dcbf/KHVI_A_2002083_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/827ec685c8dd/KHVI_A_2002083_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5d4/8920178/34426ea6ab2f/KHVI_A_2002083_F0003_OC.jpg

相似文献

[1]
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.

Hum Vaccin Immunother. 2022-12-31

[2]
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

Eur Rev Med Pharmacol Sci. 2021-2

[3]
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.

MMWR Morb Mortal Wkly Rep. 2021-9-24

[4]
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.

MMWR Morb Mortal Wkly Rep. 2021-8-13

[5]
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.

MMWR Morb Mortal Wkly Rep. 2021-8-27

[6]
Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.

Front Public Health. 2022

[7]
The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses.

J Pharm Pract. 2023-8

[8]
Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines.

Breastfeed Med. 2022-8

[9]
Performance of Three Anti-SARS-CoV-2 Anti-S and One Anti-N Immunoassays for the Monitoring of Immune Status and Vaccine Response.

Viruses. 2024-2-14

[10]
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.

Microbiol Spectr. 2021-9-3

引用本文的文献

[1]
Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.

PLoS One. 2025-9-4

[2]
Association of SARS-CoV-2 vaccination status with risk of influenza-like illness and loss of workdays in healthcare workers.

Commun Med (Lond). 2025-8-9

[3]
Situation Analysis of Immune Response Status One Year After the Nationwide COVID-19 Vaccination in Cameroon: Role of Obesity and SARS-CoV-2 Infection.

Health Sci Rep. 2025-7-18

[4]
Quantifying transmission and immunity dynamics of multiple SARS-CoV-2 variants using models and epidemic data from a highly populated area.

PLoS One. 2025-7-16

[5]
Kikuchi-Fujimoto in the light of the COVID-19: infection and vaccination. A systematic review.

Clin Rheumatol. 2025-7-3

[6]
Safflower-Derived Cationic Lipid Nanoparticles: Potential Impact on the Delivery of SARS-CoV-2 MRNA Transcripts.

Arch Razi Inst. 2024-12-31

[7]
A novel and safe SmartCap SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans.

Front Immunol. 2025-6-16

[8]
New frontiers in sickle cell disease: The role of antiviral therapies and emerging drugs in managing viral infections.

World J Virol. 2025-6-25

[9]
Mucosal and Serum Neutralization Immune Responses Elicited by COVID-19 mRNA Vaccination in Vaccinated and Breakthrough-Infection Individuals: A Longitudinal Study from Louisville Cohort.

Vaccines (Basel). 2025-5-24

[10]
Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method.

Front Immunol. 2025-6-9

本文引用的文献

[1]
Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose.

Emerg Infect Dis. 2022-7

[2]
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

Nat Med. 2021-12

[3]
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.

Lancet. 2021-10-16

[4]
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.

N Engl J Med. 2021-10-7

[5]
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2.

Elife. 2021-8-20

[6]
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.

Lancet Infect Dis. 2022-1

[7]
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.

MMWR Morb Mortal Wkly Rep. 2021-8-13

[8]
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

N Engl J Med. 2021-8-12

[9]
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.

N Engl J Med. 2021-8-12

[10]
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.

Lancet. 2021-5-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索